Correction: Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1349-4147
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction: Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar ; volume:51 ; number:1 ; day:3 ; month:2 ; year:2023 ; pages:1 ; date:12.2023
Tropical medicine and health ; 51, Heft 1 (3.2.2023), 1, 12.2023
- Urheber
-
Han, Kay Thwe
Wai, Khin Thet
Oo, Tin
Thi, Aung
Han, Zayar
Aye, Daw Kyin Hla
Win, Aung Ye Naung
Sattabongkot, Jetsumon
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41182-023-00499-8
- URN
-
urn:nbn:de:101:1-2023040809024240469071
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Han, Kay Thwe
- Wai, Khin Thet
- Oo, Tin
- Thi, Aung
- Han, Zayar
- Aye, Daw Kyin Hla
- Win, Aung Ye Naung
- Sattabongkot, Jetsumon
- SpringerLink (Online service)
Ähnliche Objekte (12)
Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar
G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination
Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa
Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination
Is it time for Africa to adopt primaquine in the era of malaria control and elimination?
Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations
On some points in the theory of elimination.
The reality of using primaquine
Primaquine: the risks and the benefits
Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar
G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination
Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa
Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination
Is it time for Africa to adopt primaquine in the era of malaria control and elimination?
Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations
On some points in the theory of elimination.
The reality of using primaquine
Primaquine: the risks and the benefits
Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar
G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination
Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa
Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination
Is it time for Africa to adopt primaquine in the era of malaria control and elimination?
Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations
On some points in the theory of elimination.
The reality of using primaquine